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Abstract
Introduction: Prior studies have demonstrated an increased frequency of antibodies to Porphyromonas gingivalis
(Pg), a leading agent of periodontal disease, in rheumatoid arthritis (RA) patients. However, these patients generally
had long-standing disease, and clinical associations with these antibodies were inconsistent. Our goal was to
examine Pg antibody responses and their clinical associations in patients with early RA prior to and after disease-
modifying antirheumatic drug (DMARD) therapy.
Methods: Serum samples from 50 DMARD-naïve RA patients were tested using an enzyme-linked immunosorbent
assay with whole-Pg sonicate. For comparison, serum samples were tested from patients with late RA, patients with
other connective tissue diseases (CTDs), age-similar healthy hospital personnel and blood bank donors. Pg antibody
responses in early RA patients were correlated with standard RA biomarkers, measures of disease activity and
function.
Results: At the time of enrollment, 17 (34%) of the 50 patients with early RA had positive immunoglobulin G (IgG)
antibody responses to Pg, as did 13 (30%) of the 43 patients with late RA. RA patients had significantly higher Pg
antibody responses than healthy hospital personnel and blood bank donors (P < 0.0001). Additionally, RA patients
tended to have higher Pg antibody reactivity than patients with other CTDs (P = 0.1), and CTD patients tended to
have higher Pg responses than healthy participants (P = 0.07). Compared with Pg antibody-negative patients, early
RA patients with positive Pg responses more often had anti-cyclic citrullinated peptide (anti-CCP) antibody
reactivity, their anti-CCP levels were significantly higher (P = 0.03) and the levels of anti-Pg antibodies correlated
directly with anti-CCP levels (P < 0.01). Furthermore, at the time of study entry, the Pg-positive antibody group had
greater rheumatoid factor values (P = 0.04) and higher inflammatory markers (erythrocyte sedimentation rate, or
ESR) (P = 0.05), and they tended to have higher disease activity scores (Disease Activity Score based on 28-joint
count (DAS28)-ESR and Clinical Disease Activity Index) and more functional impairment (Health Assessment
Questionnaire). In Pg-positive patients, greater disease activity was still apparent after 12 months of DMARD
therapy.
Conclusions: A subset of early RA patients had positive Pg antibody responses. The responses correlated with anti-
CCP antibody reactivity and to a lesser degree with ESR values. There was a trend toward greater disease activity in
Pg-positive patients, and this trend remained after 12 months of DMARD therapy. These findings are consistent
with a role for Pg in disease pathogenesis in a subset of RA patients.
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The etiology of rheumatoid arthritis (RA) is unknown,
but both environmental and genetic factors are likely to
play roles in its pathogenesis. Periodontal disease (PD),
an inflammatory disease of tooth-supporting structures,
may be an environmental trigger for RA. Compared
with healthy controls, PD is more frequent in RA
patients, both in those with new-onset and in those with
long-standing disease, even when potential confounding
factors such as smoking are taken into account [1-5].
Furthermore, there is increasing evidence of a role for
PD pathogens, particularly Porphyromonas gingivalis (Pg),
in RA pathogenesis. Pg is the only prokaryote known to
possess a peptidylarginine deiminase (PAD), an enzyme
that catalyzes the posttranslational modification of argi-
nine residues to citrulline. Although citrullination may
occur more generally in sites of inflammation, antibodies
to citrullinated proteins (anti-cyclic citrullinated peptide
(anti-CCP) antibodies) are specific for RA and are now
valuable diagnostic markers for the disease [6]. CCP anti-
b o d i e sa r ea s s o c i a t e dw i t ham o r ea g g r e s s i v ec o u r s e[ 7 ]
and may be detected prior to the onset of clinical disease
[8], suggesting a role in RA pathogenesis. Pg,t h r o u g hi t s
PAD enzyme, may citrullinate host or bacterial proteins
[9], altering their antigenicity and triggering autoimmunity
and RA in predisposed individuals [9,10]. Further support
for this hypothesis comes from animal models. Pg enolase
has been found to cause arthritis in DR4-IE-transgenic
mice [11], and Pg infection has been shown to exacerbate
collagen antibody-induced arthritis [12].
Prior studies have demonstrated increased frequencies
of antibody responses to Pg in RA patients compared with
healthy controls [5,13-16]. However, in these studies
[5,13,15,16], patients generally had long-standing disease
and were presumably receiving disease-modifying anti-
rheumatic drugs (DMARDs), factors which may affect
infection with PD pathogens and serum antibody
responses. Moreover, clinical correlations with Pg
responses have been inconsistent. Some investigators have
noted an association of Pg antibodies with anti-CCP anti-
body levels, but not with RF values [14,15], whereas others
found a correlation of Pg immunoglobulin G (IgG) antibo-
dies with RF levels, but not with CCP antibody values
[5,16]. Additionally, some researchers found an association
of Pg antibodies and elevated C-reactive protein (CRP)
levels [13,14], but others noted no correlation between
these antibodies and Disease Activity Score based on
28-joint count (DAS28)-CRP values [16].
Patients with early RA are an important group to study
because they may benefit the most from treatment inter-
ventions for Pg a n dP D .I nt h eo n l yp r e v i o u ss t u d yi n
which Pg antibodies were examined in early RA patients,
Scher et al. [4] found no significant difference in antibo-
dies to a specific Pg antigen (Pg-specific chaperone protein
HtpG) in patients with new-onset or chronic RA com-
pared with control participants. However, antibody
responses to whole-Pg antigen preparations have not yet
been reported in early RA patients. Furthermore, Pg anti-
body responses in RA patients have not been compared to
t h o s eo fp a t i e n t sw i t ho t h e rc o n n e c t i v et i s s u ed i s e a s e s
(CTDs), such as lupus, which are associated with broad
immune stimulation.
In this study, we determined Pg antibody responses in
patients with early RA and in comparison groups and cor-
related these results with standard RA biomarkers, disease
activity scores and measures of function. We report here
that both early and late RA patients had significantly more
frequent and higher IgG antibody responses to whole-Pg
sonicate antigens than healthy control participants and
tended to have higher Pg antibody reactivity than patients
with other CTDs. In early RA patients prior to DMARD
therapy, Pg antibody responses correlated significantly
with anti-CCP antibody reactivity and, to a lesser degree,
with erythrocyte sedimentation rate (ESR) values. More-
over, there was a trend toward higher disease activity and
more functional impairment in patients with Pg antibo-
dies, and these trends remained during 12 months of
DMARD therapy. Our observations are consistent with a
role for Pg in disease pathogenesis in a subset of RA
patients.
Patients and methods
Early rheumatoid arthritis cohort study and other subject
groups
Newly diagnosed adult patients with early RA were
recruited from the Rheumatology Clinic at Massachusetts
General Hospital (MGH). The study was approved by the
MGH Institutional Review Board, and written consent was
obtained from each participant. Patients with disease of
less than RA of one year’s duration who had not yet
received methotrexate (MTX) or biologic DMARD treat-
ment were eligible to participate. Study physicians calcu-
lated a classification criteria score for each patient referred
to the study, based on clinical assessment, electronic medi-
cal record (EMR) review or both. Only those patients with
as c o r e≥6/10 were included, as required by the 2010 rheu-
matoid arthritis classification criteria promulgated by the
American College of Rheumatology/European League
Against Rheumatism Collaborative Initiative [17]. For
comparison, sera were obtained from patients with long-
standing RA seen in the MGH Rheumatology Clinic. Sera
were also collected from patients with other CTDs who
were evaluated in the MGH Rheumatology Clinic or iden-
tified from the MGH Clinical Immunology Laboratory.
For healthy control groups, sera were collected from blood
bank donors and from healthy hospital personnel. Hospital
personnel did not report a history of RA or PD and were
similar in age to those in the early RA group. However,
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time of the study for any of the participants.
Clinical assessment
Clinical and laboratory assessments of the early RA
patients were performed at study entry and at 12-month
follow-up visits. Demographic data, including smoking
history, were recorded at the time of enrollment. At each
study visit, patients completed a Health Assessment Ques-
tionnaire (HAQ), and they marked a self-assessment of
global health on a 10-cm Visual Analogue Scale. Study
physicians performed a clinical assessment, including a
28-joint count, and they marked the physician’s global
disease score on a 10-cm Visual Analogue Scale. This
information was recorded in the patient’s EMR using the
rheumatology-specific, informatics-based application
Rheumatology OnCall (ROC), which was previously devel-
oped in our department [18]. The DAS28-ESR value was
automatically calculated in the ROC application, which
integrates institutional laboratory values for ESR and CRP
with physician-entered swollen and tender joint counts
and patient global DAS for each date of visit. Clinical
Disease Activity Index (CDAI) score was calculated by
study physicians using information from the ROC applica-
tion. Study physicians treated patients according to the
standard of care.
Laboratory determinations
Serum samples were collected at each visit. RF and anti-
CCP antibodies were measured at the time of study entry
in the MGH Clinical Immunology Laboratory by nephelo-
metry (IMMAGE 800; Beckman Coulter, Brea, CA, USA)
and enzyme-linked immunosorbent assay (ELISA)
(QUANTA Lite CCP3 IgG ELISA kit; INOVA Diagnostics,
San Diego, CA, USA), respectively. ESR and CRP values
were determined at each visit by MGH Clinical Labora-
tories. Serum samples from each visit were frozen at -70°C
for subsequent determinations, including Pg antibody
levels.
Pg antibody responses were determined in our labora-
tory by ELISA using a sonicate preparation of whole,
formalin-fixed Pg ATCC 33277 (American Type Culture
Collection, Manassas, VA, USA) [19]. On the day prior
to testing, 96-well polystyrene ELISA plates (Easy Wash;
Corning, Tewksbury, MA, USA) were coated with Pg
antigens (diluted 1:50) and incubated overnight at 4°C.
On the next day, each well was incubated with 200
l of blocking buffer (5% nonfat dry milk in phosphate-
buffered saline and Tween 20) at room temperature for
1 h. Following washing between each step, wells were
incubated at room temperature with 100
l of each of the following: the patient’s serum sample
(diluted 1:400) and goat anti-human IgG conjugated to
horseradish peroxidase (1:2,000), in each instance for
1.5 h, and then tetramethylbenzidine for 5 min, followed
by sulfuric acid. The absorbance was measured at 450
nm using an ELISA plate reader (Model 550; Bio-Rad
Laboratories, Hercules, CA, USA). To control for inter-
assay variation, each assay included eight serial dilutions
of a reference positive control sample as well as eight
negative control samples, and all samples from the same
patient were included on the same plate. A positive anti-
body response was defined as >2 SD above the mean
absorbance of the 19 age-similar healthy hospital per-
sonnel. Pg antibody responses were not determined until
after completion of the 12-month study period, and
therefore treatment decisions were not influenced by
these results.
Statistical analyses
Pg geometric mean antibody levels were compared
between groups by performing an unpaired t-test with
the Welch correction. Categorical data were analyzed
using Fisher’s exact test. Median values for clinical para-
meters in early RA patients were compared using the
Mann-Whitney U test. Correlations between Pg anti-
body values and clinical parameters were performed
using Pearson’s correlation test. All statistical analyses
were performed with GraphPad Prism version 5.01 soft-
ware (GraphPad Software, La Jolla, CA, USA). A P value
<0.05 was considered statistically significant. All P values
are two-tailed.
Results
Clinical characteristics of patient groups
The 50 patients with early RA–the primary study
group–were typical of a cohort of patients with this dis-
ease (Table 1). They had a median age of 52 years, were
predominantly female (72%) and the majority (84%) had
rheumatoid factor (RF) or anti-CCP antibodies, or both.
At the time of study entry, they had a median disease
duration of 4 months, and their ESR and CRP values,
disease activity scores (DAS28-ESR), tender and swollen
j o i n tc o u n t s ,C D A Ia n dH A Qr e s u l t se n c o m p a s s e dt h e
range from mild to severe disease. Only a minority
(34%) were current or former smokers. Some patients
were receiving nonsteroidal anti-inflammatory drugs or
low-dose prednisone, but, by definition, none had yet
received MTX or biologic DMARDs.
For comparison, serum samples were collected from
patients with late RA or other CTDs and from healthy
control participants (Table 2). The 43 patients with late
RA had a median disease duration of 9.5 years (range, 1 to
50 years). Most were seropositive for RF or anti-CCP anti-
bodies (86%). The majority were present or former smo-
kers (70%), and nearly all (96%) were receiving DMARD
therapy. Another CTD group included 17 patients with
lupus, and a third group consisted of 10 patients with
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CTDs. Two healthy control groups were included. One
consisted of healthy hospital personnel, and the other
included a larger group of blood bank donors.
By definition, healthy hospital personnel were selected
because they were of similar age to those in the early
RA group. Patients in the third CTD group also had
similar ages as the individuals in these groups. However,
compared with the early RA group, the lupus patients
were significantly younger (P =0 . 0 0 3 )a n dt h o s ew i t h
late RA were significantly older (P =0 . 0 1 ) .A si st y p i c a l
of these rheumatic diseases, the RA patients and other
CTD patients were predominantly female and the lupus
patients were exclusively female. The majority of age-
similar hospital personnel were men. No demographic
or clinical information about blood bank donors was
available.
Porphyromonas gingivalis immunoglobulin G antibody
responses
At study entry, the frequency of positive Pg IgG anti-
body responses and the magnitude of these responses
were highest in RA patients, intermediate in those with
other CTDs and lowest in the healthy control groups
(Figure 1). Of the 50 patients with early RA, 17 (34%)
had positive IgG antibody responses to Pg,a sd i d1 3
(30%) of the 43 patients with late RA (Figure 1A). Com-
pared with age-similar hospital personnel and blood
bank donors, Pg positivity in the early RA patients was
significantly greater in frequency (P = 0.02 and P = 0.01,
respectively) and Pg antibody levels were of significantly
greater magnitude (P = 0.002 and P = 0.001, respec-
tively). Similarly, compared with either group of healthy
participants, positive Pg IgG responses in late RA
patients were also more frequent (P =0 . 0 5a n dP =
0.04, respectively) and the levels were of greater magni-
tude (in both instances, P = 0.01). Patients with lupus or
other CTDs also had less frequent Pg antibody
responses and lower levels than both RA groups, but
greater responses than healthy control participants.
However, these differences between individual groups
were not statistically significant.
When similar groups were combined, RA patients
(early and late RA patients) had a significantly greater
mean Pg antibody response than healthy control partici-
pants (blood bank donors and age-similar healthy con-
trol individuals) (P < 0.0001) (Figure 1B). Moreover, RA
Table 1 Clinical findings at study entry in patients with
early rheumatoid arthritis
a
Parameters Data (N = 50)
Demographics
Age, years (range) 52 (30 to 80)
Sex, females/males 36/14
Smoking history, n (%)
Current 8 (16)
Former 9 (18)
Never 33 (66)
Disease duration, months 4 (1 to 12)
Autoantibodies
Rheumatoid factor (RF), no. positive (%) 30 (60)
Anti-CCP 39 (78)
RF or anti-CCP 42 (84)
Inflammatory indices
Erythrocyte sedimentation rate (ESR), mm/h
(range)
23 (3 to 98)
C-reactive protein (CRP), mg/L (range) 7.6 (0.2 to 118)
Disease activity
DAS28-ESR 4.7 (1.6 to 8.1)
Tender joint count (TJC), n (range) 8 (0 to 26)
Swollen joint count (SJC), n (range) 3 (0 to 23)
Clinical Disease Activity Index (CDAI) 19.2 (2 to 57.7)
Health Assessment Questionnaire (HAQ) 0.35 (0 to 2.55)
Medications prior to study entry, n (%)
Prednisone 13 (26)
Nonsteroidal anti-inflammatory drug (NSAID) 30 (60)
Methotrexate (MTX) 0
Tumor necrosis factor (TNF) inhibitor 0
aData are expressed as median (interquartile range) values unless otherwise
noted. Anti-cyclic citrullinated peptide: anti-CCP; DAS28: Disease Activity Score
based on 28-joint count.
Table 2 Age and sex of the early rheumatoid arthritis group and comparison groups
a
Patients
Demographic categories Age-similar
hospital
personnel
(N = 19)
Blood bank donors
(N = 53)
Systemic
lupus erythematosus
(N = 17)
Other
CTD
(N = 17)
Early
RA
(N = 50)
Late
RA
(N = 43)
Age,
mean (range)
b
48 (36 to 80) N/A 44 (25 to 59) 50 (27 to 88) 53 (30 to 80) 60 (21 to 85)
Sex,
females/males
c
7/12 N/A 17/17 15/17 36/14 31/12
aCTD: connective tissue disease; N/A: not available; RA: rheumatoid arthritis.
bFor comparison of age in early RA group vs. late RA group, P = 0.01; for early RA vs.
systemic lupus erythematosus, P = 0.003. There were no other significant differences in age among the groups.
cRegarding sex distribution, healthy hospital
personnel, who were primarily men, were significantly different from each of the patient groups, which were composed primarily of women (P ≤ 0.01). The
members of the lupus group, which was exclusively female, were significantly different than both RA patient groups (P < 0.05).
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patients with CTD (lupus and other CTDs) (P =0 . 1 ) ,
and CTD patients had a higher mean Pg response than
healthy control participants (P = 0.07), which were dif-
ferences of possible significance.
Clinical correlation of Porphyromonas gingivalis antibody
responses with anti-CCP antibodies and other standard
RA biomarkers
Consistent with typical RA cohorts, 39 (78%) of the 50
patients with early RA had anti-CCP antibody responses,
Figure 1 Porphyromonas gingivalis immunoglobulin G antibody responses. Porphyromonas gingivalis (Pg) antibody responses are shown in
age-similar healthy hospital personnel and blood bank donors, in patients with early or late RA and in patients with other connective tissue
diseases (CTDs), including 17 patients with lupus and another group consisting of 10 patients with Sjögren syndrome, 4 with scleroderma and 3
with mixed CTD. (A) All data points are shown for each individual group. (B) The results are summarized, and data from all healthy control
participants and patients with CTD or RA are combined. In (B), the histograms give the mean values, and I-bars show the standard error of the
mean. The shaded region represents <2 SD above the mean absorbance of healthy hospital personnel. Abs: absorbance; IgG: immunoglobulin G.
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In contrast, only 1 (6%) of the 17 patients with lupus and
1 (6%) of the 17 patients with another CTD had border-
line low-level anti-CCP antibody reactivity. Of the two
anti-CCP antibody-positive patients with other CTD, the
one with lupus was thought to have a lupus-RA overlap
syndrome and the other had scleroderma but not arthri-
tis. Neither patient had positive Pg antibody responses.
None of the 19 age-similar healthy control participants
had CCP antibody responses. These differences between
RA patients and the other groups were highly significant
(P < 0.0001).
In the early RA patients, the primary study group, Pg
antibody responses were correlated with anti-CCP anti-
body reactivity and other standard RA biomarkers. At the
time of study entry, 15 (88%) of the 17 early RA patients
with positive Pg antibody responses had elevated CCP
antibody levels compared with 24 (72%) of the 33 patients
with negative Pg antibody responses (P = 0.3). Moreover,
CCP antibody levels were significantly higher in patients
with positive Pg antibody responses than in those who
lacked Pg reactivity (P = 0.03), and the levels of Pg antibo-
dies correlated directly with anti-CCP levels (r = 0.37, P <
0.01) (Figure 3A). Similarly, 13 (76%) of the 17 early RA
patients with positive Pg antibody responses had positive
results for RF, compared with 18 (55%) of the 33 patients
who did not have Pg antibodies (P =0 . 2 ) .A l t h o u g hR F
values were higher in those with Pg antibody reactivity
(P = 0.04), there was no correlation between the magni-
tude of RF and Pg antibody responses.
In addition, 13 (76%) of the 17 patients with positive Pg
antibody responses had elevated ESR levels compared with
18 (55%) of the 33 patients who lacked Pg antibodies (P =
0.2). Furthermore, ESR values were significantly higher in
patients with positive Pg antibody responses (P < 0.05),
and ESR levels correlated with Pg antibody levels (r =0 . 3 2 ,
P = 0.03) (Figure 3B). Patients with positive Pg antibody
responses also had higher CRP values, but the magnitude
of these values did not correlate significantly with Pg anti-
body responses. Overall, although most patients had posi-
tive test results for RF and anti-CCP autoantibodies and
elevated inflammatory markers, the values were higher in
the group with Pg antibodies.
Measurements of disease activity and function prior to
and after disease-modifying antirheumatic drug therapy
At the time of study entry, prior to DMARD therapy,
there was a trend toward higher disease activity scores
(DAS28-ESR) in early RA patients with positive Pg anti-
body responses. Additionally, ESR values were signifi-
cantly greater in those with positive Pg antibodies
(Figure 4). The CDAI levels were also slightly higher in
the Pg antibody-positive group. HAQ scores, a func-
tional measure, also tended to be higher (indicating a
greater degree of dysfunction) in patients with positive
Pg antibody responses than in those with negative Pg
Figure 2 Anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis patients and comparison groups. Anti-cyclic citrullinated
peptide (anti-CCP) antibody responses are shown in age-similar healthy hospital personnel, patients with connective tissue diseases and early
and late rheumatoid arthritis patient groups. Mean values and standard errors of the mean are shown, and the shaded region represents
negative values.
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early rheumatoid arthritis (RA), the levels of autoantibodies (anti-cyclic citrullinated peptide (anti-CCP) (A) and rheumatoid factor (RF)) and
inflammatory markers (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) (B) were compared at study entry in the 17 patients
with positive Porphyromonas gingivalis (Pg) antibody responses and in the 33 patients with negative Pg antibody reactivity, as shown in the left
panels. In the right panels, the levels of each RA biomarker are correlated with Pg immunoglobulin G antibody levels (Pearson correlation
coefficients). Median values and interquartile ranges are shown, and the shaded regions represent normal values. Ab: antibody; OD: optical
density.
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Moreover, the degree of dysfunction correlated directly
with the magnitude of Pg antibody reactivity (r =0 . 3 ,P
= 0.05; data not shown). Surprisingly, a history of past
or present smoking tended to be more common among
patients who lacked Pg antibody responses than in those
who had Pg reactivity (42% vs. 18%; P =0 . 1 ) .F u r t h e r -
more, compared with patients who lacked Pg antibodies,
Figure 4 Disease activity prior to and after 12 months of disease-modifying antirheumatic drug treatment. Disease activity scores and
functional measures ( Disease Activity Score based on 28-joint count erythrocyte sedimentation rate (DAS28-ESR), ESR, Clinical Disease Activity Index
(CDAI), and Health Assessment Questionnaire (HAQ)) are shown according to Porphyromonas gingivalis (Pg) antibody status at the time of study
entry, prior to disease-modifying antirheumatic drug therapy and after 12 months of treatment. Data were available at the time of study entry for
all 17 Pg-positive and all 33 Pg-negative patients. At the 12-month follow-up visits, data for DAS28-ESR, ESR and CDAI were available from 16
Pg-positive and 22 Pg-negative patients. For the HAQ, data were available from 12 Pg-positive and 22 Pg-negative patients. Median values and
interquartile ranges are shown, and the shaded regions represent normal or negative values. Although disease activity measures declined in both
groups during the 12-month period, patients with Pg antibodies tended to have higher values, primarily for ESR and DAS28-ESR.
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often treated with prednisone prior to study entry (41%
vs. 18%; P = 0.1), presumably because of more severe
disease.
After their first visit, all 50 patients with early RA
were treated with DMARDs, usually MTX, and in some
cases TNF inhibitors. During the following 12-month
period, Pg antibody levels remained the same or
declined slightly (data not shown), and no patient with
an initial negative Pg antibody response developed a
positive response during the study period. Conversely,
the ESR and disease activity measures (DAS28-ESR and
CDAI) generally improved, and functional scores (HAQ)
usually returned to normal. However, compared with
patients who lacked Pg antibody responses, those with
positive Pg responses still tended to have higher DAS28-
ESR scores and significantly higher ESR values at the
12-month follow-up visit (Figure 4). Moreover, at 12
months, only 6 (38%) of the 16 patients who had posi-
tive Pg antibody responses achieved DAS28 remission
compared with 14 (64%) of the 22 patients who lacked
Pg antibodies (P = 0.2), though this trend was not statis-
tically significant. Thus, in patients with elevated Pg
antibodies, the trend toward greater disease activity, as
measured by DAS28 scores, remained after 12 months
of DMARD therapy.
Discussion
In this study, 34% of patients with early RA, prior to
DMARD therapy, had positive IgG antibody responses to
Pg. These antibody responses were of significantly greater
frequency and magnitude than those of age-similar healthy
hospital personnel or blood bank donors. Most of the RA
patients were women, and the majority of hospital person-
nel were men. Although men may carry a greater risk of
PD than women [20], a highly significant difference was
still shown between the RA patients and healthy partici-
pants. In addition, Pg antibody levels in early RA patients
were similar to or even higher than those in late RA
patients, even though the latter group had more risk fac-
tors for PD, including older age and more frequent smok-
ing history [21]. Furthermore, the similar or higher Pg
antibody levels in DMARD-naïve early RA patients com-
pared with DMARD-treated late RA patients suggest that
immunosuppression from DMARD therapy did not alter
or enhance Pg antibody reactivity. Although 26% of the
early RA patients at the time of enrollment were receiving
steroids, which may potentially lower antibody levels, Pg
antibody levels tended to be higher in patients receiving
steroids, suggesting that steroid treatment did not decrease
Pg antibody levels.
We also included a comparison group consisting of
patients with other CTDs typically associated with sys-
temic inflammation and autoantibody production,
including lupus, mixed CTD, Sjögren syndrome or sclero-
derma. About 20% of these patients had positive antibody
responses to Pg, which was a lesser percentage than RA
patients (34%) but greater than age-similar healthy control
participants (5%). We hypothesize that Pg reactivity in
patients with other CTD may have been caused by PD,
nonspecific immune stimulation or both. However,
because almost all of the patients with other CTDs lacked
anti-CCP antibodies, cross-reactivity with citrullinated
proteins does not appear to account for increased Pg reac-
tivity in the non-RA patient groups. Thus, we conclude
that a subset of RA patients seen early in the illness prior
to DMARD therapy have positive Pg IgG antibody
responses, which were more frequent and of higher mag-
nitude than those in individuals in the other groups we
tested.
Determining which Pg antigens to use for serologic
t e s t si sp r o b l e m a t i c .U s i n gw h o l e - Pg lysates, a Pg-speci-
fic lipopolysaccharide or recombinant citrullinated Pg
PAD, other investigators have previously demonstrated
increased frequencies of Pg antibody responses in
patients with chronic RA compared with healthy control
participants [5,13-16,22], as we did using whole-sonicate
antigens. In the only previous study of new-onset RA
patients, antibody responses to Pg specific chaperone
protein HtpG were not significantly different from those
in healthy control participants [4]. However, antibody
responses to this protein may protect against PD and
may even be higher in healthy subjects [23]. In our
study, we chose to use whole-sonicate antigens because
little is known about the frequencies of reactivity with
specific Pg antigens, even in patients with PD. There-
fore, the use of whole-sonicate antigens, which encom-
pass many Pg proteins, would increase the possibility of
detecting responses. Although such preparations would
presumably also increase the potential for false-positive
results because of cross-reacting antibodies to other
organisms or cross-reactivity between bacterial and host
citrullinated proteins [24], we attempted to address this
issue by testing serum samples from multiple compari-
son groups. Future serologic studies using multiple
types of assays, such as ELISA and Western blot analy-
sis, as well as different antigen preparations, including
noncitrullinated Pg proteins, will be important to define
further the sensitivity and specificity of Pg antibody
responses in RA patients.
In our study, a limitation in our ability to interpret Pg
antibody responses is the lack of dental examinations in
case and control participants. In our study, the cutoff
value for a positive response was 2 SD above the mean
value in the age-similar healthy control participants who
reported no history of PD. Yet, it is possible that some
of these individuals had PD, which might obscure a dif-
ference between RA patients and control participants.
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between these groups. Others have previously noted an
increased frequency of PD in RA patients [1-5]. Pg anti-
body responses correlate well with the presence of PD
[25], and higher Pg antibody titers and DAS28 scores
have been noted in RA patients with more severe PD
[5]. However, Pg antibodies may also be associated with
a host protective response or carriage of Pg as a com-
mensal opportunistic pathogen [23,26]. Therefore, in
future studies, it will be important to perform Pg anti-
body studies along with dental examinations, as we have
now initiated in our cohort.
In addition to RA, increased frequencies and severity of
PD have been reported in several other rheumatic diseases,
including ankylosing spondylitis [27], scleroderma [28]
and psoriatic arthritis [29]. Although patients with Sjögren
syndrome have xerostomia, periodontitis does not seem to
be more frequent in these patients [30]. In addition to Pg
reactivity, antibody responses to several other PD patho-
gens have been found in RA patients, including Prevotella
intermedia, Prevotella melaninogenica, Actinobacillus acti-
nomycetemcomitans and Bacteroides forsythus [13,16].
Thus, among rheumatic diseases, increased frequencies of
PD may not be unique to RA and increased frequencies of
positive antibody responses to PD pathogens may include
organisms other than Pg.
What does seem to be unique in RA is the association
between Pg and anti-CCP antibody responses. Consistent
with previous reports [14,15], our early RA patients with
Pg antibodies more often had anti-CCP antibody reactivity.
Their anti-CCP responses were significantly higher, and
the levels of anti-Pg antibodies correlated directly with
anti-CCP levels. In contrast, anti-CCP antibody responses
were rarely found in patients with other CTDs, and, if pre-
sent, the levels were very low. Moreover, these responses
were not present in healthy control participants. Mikuls et
al. recently noted that Pg antibodies may be present prior
to the development of synovitis [31], and, in our study, no
patient who initially had negative results for Pg antibodies
developed these antibodies during 12 months of DMARD
therapy. Taken together, these observations suggest that
immunity to Pg is one factor that may set the stage for
autoimmunity and inflammatory synovitis in a subset of
RA patients.
Citrullination of proteins may occur within the joint
as well as at other sites of inflammation, such as
the lung and periodontium [32,33]. In our study,
Pg- n e g a t i v eR Ap a t i e n t sw e r em o r el i k e l yt ob es m o -
kers, suggesting that the lung, rather than the gingiva,
may have been the site of protein citrullination in
these patients. Further studies which examine the lung
and periodontium in RA patients are needed to evalu-
ate this hypothesis. Although Pg may be involved in
RA pathogenesis through citrullination, there may be
other important mechanisms by which Pg contributes
to disease activity in RA. For example, the organism
may be more likely to skew CD4+ T-cell reactivity to a
Th17 phenotype [34], a response which has been
implicated in autoimmunity [35].
Despite specific mechanisms that may account for the
association of Pg immunity with RA, we found, as others
have [5,14,16], that RF, general markers of inflammation
(ESR), scores of disease activity (DAS28 and CDAI) and
functional impairment (HAQ) were also greater in patients
with Pg antibody responses. Moreover, the trends
remained for the DAS28-ESR and ESR values during 12
months of DMARD therapy. Although the CDAI scores
were also slightly higher in the Pg antibody-positive group,
the differences were not as great as those in the DAS28-
ESR, suggesting that ESR is an important contributor to
differences in disease activity scores between the groups.
Thus, Pg antibodies may simply be a marker for PD, a
chronic inflammatory condition that may itself be asso-
ciated with elevation of inflammatory markers. However,
the trend toward more severe disease activity in Pg anti-
body-positive patients using indices (HAQ and CDAI) that
do not incorporate inflammatory markers suggests that Pg
itself may contribute to RA disease activity.
There are possible confounding issues in the association
of Pg antibody reactivity with greater disease activity in
RA. For example, certain health behaviors, such as lack of
routine dental care, might extend to noncompliance with
RA treatment. Factors not studied here, such as the shared
epitope (SE), may contribute to the severity of PD [36] as
well as RA, and the SE has been associated with periodon-
tal bone destruction in RA patients [37]. However, other
studies in RA patients have not found a correlation
between the SE and PD or Pg antibodies [5,14]. Because of
the heterogeneous environmental and host factors
involved in RA, patient cohorts may vary, accounting for
inconsistent results in clinical correlations among studies
[4,5,14-16]. However, consistent with our results, there is
general agreement that Pg immunity is associated with
greater inflammation in RA patients.
In a preliminary study of patients with established RA,
Ortiz et al. reported that disease activity, as measured by
DAS28 score and swollen joint counts, improved with
nonsurgical treatment of PD [38]. Pg antibodies as a mar-
ker for PD may prove to be useful in the identification of
patients who would benefit from such treatments. It will
be particularly important to conduct studies of therapies
for PD and Pg in patients with early RA because PD treat-
ment may make the most difference in early stages of the
disease.
Conclusions
A subset of early DMARD-naïve RA patients had posi-
tive Pg antibody responses which were more frequent
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other CTDs or healthy control participants. Compared
with patients who lacked Pg antibodies, those with posi-
tive Pg responses more often had anti-CCP antibody
reactivity, their anti-CCP levels were significantly higher
and the levels of anti-Pg antibodies correlated directly
with anti-CCP levels. Furthermore, there was a trend
toward higher disease activity and more functional
impairment in patients with Pg antibody responses, and
these trends remained during 12 months of DMARD
therapy. These findings are consistent with a role for Pg
in disease pathogenesis in a subset of RA patients.
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